Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RD-Cy7
- Development stage
- Phase 1
- Lead developer
- Chinese Academy of Sciences
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous (based On Typical Use In Intraoperative Imaging; Specific Route Not Explicitly Stated But Inferred From Context)
01
Overview
RD-Cy7 is a small molecule near-infrared (NIR) fluorescent probe designed for diagnostic imaging, specifically as an enhancer for intraoperative fluorescence imaging. It functions as an antagonist of integrin subunit alpha 6 (ITGA6), targeting this protein to improve the detection and surgical resection of hepatocellular carcinoma lesions. The drug was developed by the Institute of Automation Chinese Academy of Sciences and is currently being evaluated in Phase 1 clinical trials for its safety and effectiveness in image-guided surgery for hepatocellular carcinoma[1]. Its mechanism leverages NIR-II fluorescence molecular imaging, which benefits from increased tissue transparency in this spectral region, allowing improved visualization during tumor resection.
- Other names
- RD-Cy7 fluorophoreRD-Cy-7 fluorophoreRD-Cy 7 fluorophore
02
Targets
ITGA6 (Integrin alpha-6)
Beyond the preview
Go deeper on RD-Cy7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RD-Cy7.